The Latest Breaking News from Zoetis

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Despite Zoetis lagging behind the broader market over the past year, analysts still remain strongly bullish on the stock’s prospects.

As Zoetis is all set to announce its second-quarter earnings next month, analysts project a single-digit improvement in its bottom line.

The pet care industry’s robust expansion is driven by rising disposable income, adoption of e-commerce platforms, and rising pet ownership. Therefore, investors could consider watching fundamentally sound pet care stocks, Zoetis (ZTS), IDEXX Laboratories (IDXX), and Chewy (CHWY). Keep reading.

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

Despite Zoetis significantly trailing behind the Nasdaq Composite over the past three months, analysts seem extremely bullish on the stock’s prospects due to its robust product pipeline and global reach.

In today's uncertain economic landscape, marked by high inflation, high rates, and global uncertainty, here are three resilient 'Strong Buy' dividend stocks that investors can consider for long-term returns.